Atavistik Bio Presents Preclinical Data on Precision Oncology Development Candidate, ATV-1601, a Selective Allosteric AKT1 E17K Small Molecule Inhibitor, at EORTC-NCI-AACR Symposium
October 23, 2024 06:00 ET
|
Atavistik Bio, Inc.
Atavistik Bio presents preclinical data on precision oncology development candidate, ATV-1601, a selective allosteric AKT1 E17K small molecule inhibitor.
Atavistik Bio Announces Nomination of Precision Oncology Development Candidate, ATV-1601, a Selective Allosteric AKT1 E17K Small Molecule Inhibitor
October 15, 2024 07:00 ET
|
Atavistik Bio, Inc.
AKT1 E17K mutation is a clinically validated oncogene that impacts greater than 40,000 cancer patients per year in the United States, with the highest prevalence in breast, endometrial, and prostate...
Atavistik Bio Appoints Oncology Clinical Development Leader Mohammad Hirmand, M.D. to Board of Directors
September 25, 2024 07:00 ET
|
Atavistik Bio, Inc.
Atavistik Bio announced today the appointment of oncology clinical development leader Mohammad Hirmand, M.D. to its Board of Directors.
Atavistik Bio Strengthens Leadership Team with Appointment of Paul Bruno, Ph.D. as Chief Business Officer
August 12, 2024 06:30 ET
|
Atavistik Bio, Inc.
Atavistik Bio, focused on discovering the next generation of precision allosteric therapeutics, announces the appointment of Paul Bruno, Ph.D. as CBO.
Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeutics
December 19, 2023 07:00 ET
|
Atavistik Bio, Inc.
Atavistik Bio announced that it has raised an additional $40 million to advance its precision allosteric small molecule therapeutic pipeline.
Atavistik Bio Appoints Bryan Stuart as Chief Executive Officer
July 17, 2023 07:00 ET
|
Atavistik Bio, Inc.
Mr. Stuart brings more than 25 years of biopharma executive leadership, corporate strategy, and business development experience to guide Atavistik Bio’s advancing discovery pipelineJeff Goater,...
Atavistik Bio Announces Publication in Science by Co-Founder Jared Rutter Describing Foundational Technology for its Atavistik Metabolite-Protein Screening (AMPS) Platform
March 13, 2023 08:00 ET
|
Atavistik Bio, Inc.
MIDAS (mass spectrometry integrated with equilibrium dialysis for the discovery of allostery systematically), in-licensed and industrialized by Atavistik Bio as the basis of AMPS, is the first...
Atavistik Bio Announces Collaboration with Plex Research to Enrich the Informatics Capabilities of its AMPS Platform and Accelerate the Discovery of Novel Small Molecule Therapeutics
January 10, 2023 08:00 ET
|
Atavistik Bio, Inc.
CAMBRIDGE, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Atavistik Bio, a biotechnology company focused on revolutionizing the discovery of new allosteric protein-metabolite interactions to develop novel...